OncoBeta®, with its headquarters located in Garching near Munich, Germany, is a privately held medical device company, specializing in the development and commercialization of state-of-the-art, innovative therapies. Since its foundation, OncoBeta has concentrated its efforts on the development, regulatory approval(s) and commercialization of the epidermal radioisotope therapy Rhenium-SCT® (Skin Cancer Therapy), targeting NMSCs. OncoBeta has perfected the customized application and device management system in conformity with all health, safety and environmental protection regulatory standards.

Find out more about the Rhenium-SCT® at www.oncobeta.com

Follow us on social media:
LinkedIn: www.linkedin.com/company/oncobeta-gmbh/
Facebook: www.facebook.com/oncobeta/
Instagram: www.instagram.com/oncobeta_gmbh/

Our Products

About the Rhenium-SCT® (Skin Cancer Therapy)

Non-melanoma skin cancer (NMSC) is the most common form of cancer in humans.1 The most common cause of NMSC is sun exposure, while other predisposing factors include genetic skin conditions and immunosuppressive diseases or treatments.2

The Rhenium-SCT® is a painless*, single session†, non-invasive therapy that provides aesthetic results, even in cases otherwise considered difficult to treat.3-5 The Rhenium-SCT utilizes the radioisotope Rhenium-188 in an epidermal application with optimal properties for the treatment of NMSCs (non-melanoma skin cancers). The Rhenium-SCT is a precise, personalised therapy that is only applied to the area needed to treat, therefore sparing healthy tissue. The specially designed therapy application ensures the Rhenium-SCT compound never comes in direct contact with the patient’s skin and the application is safe and simple for the applying physician. Most cases of NMSCs (Basal Cell Carcinomas and Squamous Cell Carcinomas) can be treated using the Rhenium-SCT in one single session.†5 Scar-free healing of the treated lesion area and the regeneration of healthy tissue occurs usually within a few weeks after treatment.5

188W/188Re Generator

The OncoBeta® 188W/188Re Generator is based on an alumina column. The longer-lived mother radionuclide 188W is adsorbed on the column material while the daughter radionuclide 188Re is selectively eluted from the generator with sterile isotonic solution as sodium perrhenate (Na188ReO4).

The 188W/188Re Generator can be used for radiolabelling reactions or directly as a high dose liquid radioactive source. Not for human use.

*No reported pain3,4
Complete tumour regression in 98.5% of lesions treated, with 89% after a single application5


  1. Ciążyńska M, et al. Sci Rep. 2021;11(1):4337.
  2. net. Skin Cancer (Non-Melanoma): Risk Factors and Prevention. October 2020. https://www.cancer.net/cancer-types/skin-cancer-non-melanoma/risk-factors-and-prevention (accessed March 2022).
  3. Cipriani C, et al. J Dermatolog Treat. 2020; Jul 22:1-7.
  4. Sedda AF, et al. Clin Exp Dermatol. 2008;33(6):745-749.
  5. Cipriani C, Sedda AF. Epidermal Radionuclide Therapy - Dermatological High-Dose-Rate. Brachytherapy for the Treatment of Basal and Squamous Cell Carcinoma. In: Therapeutic Nuclear Medicine, editor Baum RP; New York: Springer, 2014.